Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Xu, Chun Hua ^a,b   Yu, Li Ke ^a,b   Hao, Ke Ke ^a,b  

^a NANJING CHEST HOSPITAL   (China)

^b Center for Diseases Control of Nanjing   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; IRINOTECAN; TUMOR MARKER; UNCLASSIFIED DRUG; YKL 40 PROTEIN; ADIPOCYTOKINE; ANTINEOPLASTIC AGENT; CHI3L1 PROTEIN, HUMAN; LECTIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG RESPONSE; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SMALL CELL LUNG CARCINOMA;

ADIPOKINES; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LECTINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; ROC CURVE; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84900437031     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096384     Document Type: Article

References (29)

1. Chen Z, Wang T, Cai L, Su C, Zhong B, et al. (2012) Clinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells. J Exp Clin Cancer Res 31: 10.
2. Maddison P, Thorpe A, Silcocks P, Robertson JF, Chapman CJ (2010) Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer 70: 335-339.
3. J Barata F, Costa AF (2007) Small cell lung cancer-state of the art and future perspectives. Rev Port Pneumol 13: 587-604.
4. Govindan R, Page N, Morgensztern D, Read W, Tierney R, et al. (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24: 4539-4544. (Pubitemid 46630948)
5. Free CM, Ellis M, Beggs L, Beggs D, Morgan SA, et al. (2007) Lung cancer outcomes at a UK cancer unit between 1998-2001. Lung Cancer 57: 222-228. (Pubitemid 47043182)
6. Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, et al. (2013) Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer 80: 45-49.
7. Tufman A, Huber RM (2010) Biological markers in lung cancer: A clinician's perspective. Cancer Biomark 6: 123-135.
8. Grunnet M, Sorensen JB (2012) Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76: 138-143.
9. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA (2006) Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15: 194-202. (Pubitemid 43342164)
10. Bi J, Lau SH, Lv ZL, Xie D, Li W, et al. (2009) Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol 40: 1790-1797.
11. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, et al. (2006) Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 24: 798-804. (Pubitemid 46622047)
12. Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, et al. (2008) Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 25: 801-809.
13. Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, et al. (2009) YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 9: 8.
14. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, et al. (2004) Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 22: 3330-3339. (Pubitemid 41103690)
15. Jensen BV, Johansen JS, Price PA (2003) High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 9: 4423-4434. (Pubitemid 37248400)
16. Wang D, Zhai B, Hu F, Liu C, Zhao J, et al. (2012) High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One 7: e51127.
17. Saidi A, Javerzat S, Bellahcene A, De Vos J, Bello L, et al. (2008) Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 122: 2187-2198. (Pubitemid 351542321)
18. Choi IK, Kim YH, Kim JS, Seo JH (2010) High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer. Acta Oncol 49: 861-864.
19. Johansen JS, Drivsholm L, Price PA, Christensen IJ (2004) High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 46: 333-340. (Pubitemid 39487308)
20. Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, et al. (2010) Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 116: 4114-4121.
21. van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011) Small-cell lung cancer. Lancet 378: 1741-1755.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
23. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, et al. (2009) Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13- induced tissue responses and apoptosis. J Exp Med 206: 1149-1166.
24. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, et al. (2009) YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28: 4456-4468.
25. Zou L, He X, Zhang JW (2010) The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Braz J Med Biol Res 43: 1232-1238.
26. Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, et al. (2009) Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol 20: 71-77.
27. Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, et al. (2013) Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS One 8: e67059.
28. Gronlund B, Høgdall EV, Christensen IJ, Johansen JS, Nørgaard-Pedersen B, et al. (2006) Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125). Int J Biol Markers 21: 141-148. (Pubitemid 44660285)
29. Mylin AK, Andersen NF, Johansen JS, Abildgaard N, Heickendorff L, et al. (2009) Serum YKL-40 and bone marrow angiogenesis in multiple myeloma. Int J Cancer 124: 1492-1494.